Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications

Lancet Oncology

Volumn 2, Issue 11, 2001, Pages 667-673

  Toi, Masakazu ^a   Matsumoto, Tomoe ^b   Bando, Hiroko ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Base Technology Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; MITOGENIC AGENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ANGIOGENESIS; ARTHRALGIA; BLEEDING; BLOOD VESSEL; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL OBSERVATION; DRUG MECHANISM; DRUG RESISTANCE; DRUG SYNTHESIS; DRUG TOXICITY; ENDOTHELIUM CELL; FATIGUE; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERTENSION; INHIBITION KINETICS; MOLECULE; MYALGIA; NEOVASCULARIZATION (PATHOLOGY); NEURALGIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; STEM CELL; TREATMENT PLANNING;

EID: 0035187771     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00556-3     Document Type: Review

References (51)

1. VEGF: An update on biological and therapeutic aspects
2. Clinical applications of angiogenic growth factors and their inhibitors
3. Soluble VEGF receptors
4. Vascular endothelial growth factor receptor-1 (VEGFR-1) and neuropilin-2 form complexes
5. VEGF-D promoter the metastaic spread of tumor cells via the lymphatics
6. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
7. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
8. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
9. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
10. Isolation of putative progenitor endothelial cells for angiogenesis
11. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
12. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells
13. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
14. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
15. How tumors become angiogenic
16. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
17. Up-regulation of hypoxia-inducible factors HIF- 1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
18. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
19. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
20. Neutralizing antibodies against epidermal growth factor and ERBB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic transduction therapy of solid tumors
21. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factors
22. Clinical implications of circulating angiogenic factors in cancer patients
23. Specificity, diversity, and convergence in VEGF and TNF-alfa signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells
24. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
25. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
26. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
27. BCL-2 and c-ERBB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer
28. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer
29. Angiogenesis and cancer metastasis
30. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer
31. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer
32. Angiostatin expression in non-small cell lung cancer
33. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
34. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth pleiotrophin in human primary breast cancer and its relation to angiogenesis
35. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
36. P53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
37. Markers of tumor angiogenesis and proteolysis independently define high- and low- risk subsets of node-negative breast cancer patients
38. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue
39. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx
40. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
41. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
42. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy
43. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
44. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
45. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo
46. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study
47. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
48. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
49. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
50. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
51. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity